Equillium targets Q4 Phase I start for ulcerative colitis drug EQ504

Equillium is targeting a fourth-quarter start for a Phase I trial of EQ504, its drug candidate for ulcerative colitis, according to a report on the company's plans.

Detected & updated continuously · Source: Nebula